Across TCGA pan-cancer cohorts, IGHV1-46 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IGHV1-46 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher IGHV1-46 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGHV1-46 expression acts as an unfavorable survival marker.

KIRP, SKCM, and LUAD are the cancer types where IGHV1-46 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.161	0.904	<.001	27	view →
SKCM	DFS	Median	II,III,IV	0.087	0.708	<.001	20	view →
LUAD	OS	Median	III,IV	0.083	0.680	<.001	12	view →
PRAD	DFS	Median	All	0.617	0.886	.011	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: IGHV1-46 tumor-vs-normal RNA expression · all IGHV1-46 data types